BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) ...

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...

BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS ...

Just weeks after DoorDash reported a stellar Q4, the company has announced it will buy Bbot, a startup that makes order-and-pay software for restaurants and other hospitality venues. The acquisition ...

DoorDash announced Tuesday its intention to acquire startup ordering and payment solutions platform, Bbot. The deal is expected to be finalized by the end of this quarter and will introduce tableside ...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...

Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed ...

Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.

Every time Troy publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from Business ...

DoorDash is acquiring Bbot, a hospitality technology startup. The acquisition will offer merchants more solutions for their in-store and online channels, including in-store digital ordering and ...

As bars and restaurants across the globe contemplate how to safely serve diners during the pandemic, many establishments are seeking ways to reduce the number of touchpoints between servers and guests ...

Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.